FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165087351> ?p ?o ?g. }

• W2165087351 endingPage "1721" @default.
• W2165087351 startingPage "1715" @default.
• W2165087351 abstract "IntroductionThis post hoc analysis evaluated the efficacy of indacaterol, a novel inhaled once-daily long-acting β2-agonist, by disease severity (GOLD 2005) in patients with moderate-to-severe COPD from six Asian countries/areas (Hong Kong, India, Japan, Korea, Singapore, Taiwan).MethodsData from a 12-week, double-blind, placebo-controlled, parallel-group study in patients randomized to indacaterol 150 μg, indacaterol 300 μg or placebo once daily were analyzed based on baseline disease severity (moderate or severe). Endpoints were: trough FEV1 (average of 23 h 10 min and 23 h 45 min post-dose values), transition dyspnoea index (TDI) and St George's Respiratory Questionnaire (SGRQ) at Week 12. Safety data were collected.ResultsOf 347 patients randomized, 59.7% had moderate, and 40.3% had severe COPD. Least squares means (LSMs) indacaterol–placebo differences in trough FEV1 at Week 12 exceeded the pre-specified minimal clinically important difference (MCID) of 0.12L and were statistically superior (p < 0.001) for indacaterol (150 μg, 300 μg) versus placebo in the two subgroups [0.19L, 0.20L (moderate); 0.15L, 0.19L (severe) respectively]. LSM TDI scores for both indacaterol doses versus placebo in both subgroups were statistically superior (p < 0.05) and clinically meaningful (≥1 unit). Both indacaterol doses showed improvements in LSM SGRQ total scores at Week 12 which exceeded the MCID (4 units) versus placebo in both subgroups, with indacaterol 300 μg–placebo difference in the severe subgroup being statistically significant (p < 0.01). Overall incidence of adverse events was lower with indacaterol than with placebo across both subgroups.ConclusionsIndacaterol demonstrated clinically relevant improvements versus placebo in lung function, dyspnea and health status in Asian COPD patients irrespective of disease severity.Clinical Trials IdentifierNCT00794157. This post hoc analysis evaluated the efficacy of indacaterol, a novel inhaled once-daily long-acting β2-agonist, by disease severity (GOLD 2005) in patients with moderate-to-severe COPD from six Asian countries/areas (Hong Kong, India, Japan, Korea, Singapore, Taiwan). Data from a 12-week, double-blind, placebo-controlled, parallel-group study in patients randomized to indacaterol 150 μg, indacaterol 300 μg or placebo once daily were analyzed based on baseline disease severity (moderate or severe). Endpoints were: trough FEV1 (average of 23 h 10 min and 23 h 45 min post-dose values), transition dyspnoea index (TDI) and St George's Respiratory Questionnaire (SGRQ) at Week 12. Safety data were collected. Of 347 patients randomized, 59.7% had moderate, and 40.3% had severe COPD. Least squares means (LSMs) indacaterol–placebo differences in trough FEV1 at Week 12 exceeded the pre-specified minimal clinically important difference (MCID) of 0.12L and were statistically superior (p < 0.001) for indacaterol (150 μg, 300 μg) versus placebo in the two subgroups [0.19L, 0.20L (moderate); 0.15L, 0.19L (severe) respectively]. LSM TDI scores for both indacaterol doses versus placebo in both subgroups were statistically superior (p < 0.05) and clinically meaningful (≥1 unit). Both indacaterol doses showed improvements in LSM SGRQ total scores at Week 12 which exceeded the MCID (4 units) versus placebo in both subgroups, with indacaterol 300 μg–placebo difference in the severe subgroup being statistically significant (p < 0.01). Overall incidence of adverse events was lower with indacaterol than with placebo across both subgroups. Indacaterol demonstrated clinically relevant improvements versus placebo in lung function, dyspnea and health status in Asian COPD patients irrespective of disease severity." @default.
• W2165087351 created "2016-06-24" @default.
• W2165087351 creator A5007157113 @default.
• W2165087351 creator A5017368316 @default.
• W2165087351 creator A5025484018 @default.
• W2165087351 creator A5027940462 @default.
• W2165087351 creator A5048294207 @default.
• W2165087351 creator A5048910830 @default.
• W2165087351 creator A5051698789 @default.
• W2165087351 creator A5058327886 @default.
• W2165087351 creator A5060123928 @default.
• W2165087351 creator A5071574732 @default.
• W2165087351 creator A5083127780 @default.
• W2165087351 date "2012-12-01" @default.
• W2165087351 modified "2023-09-26" @default.
• W2165087351 title "Assessing efficacy of indacaterol in moderate and severe COPD patients: A 12-week study in an Asian population" @default.
• W2165087351 cites W1897953485 @default.
• W2165087351 cites W1952594708 @default.
• W2165087351 cites W2004780292 @default.
• W2165087351 cites W2020662437 @default.
• W2165087351 cites W2044624199 @default.
• W2165087351 cites W2066043730 @default.
• W2165087351 cites W2071738192 @default.
• W2165087351 cites W2089834473 @default.
• W2165087351 cites W2112433656 @default.
• W2165087351 cites W2117079401 @default.
• W2165087351 cites W2122786331 @default.
• W2165087351 cites W2125779455 @default.
• W2165087351 cites W2130703359 @default.
• W2165087351 cites W2154834980 @default.
• W2165087351 cites W2160587269 @default.
• W2165087351 doi "https://doi.org/10.1016/j.rmed.2012.09.002" @default.
• W2165087351 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23040786" @default.
• W2165087351 hasPublicationYear "2012" @default.
• W2165087351 type Work @default.
• W2165087351 sameAs 2165087351 @default.
• W2165087351 citedByCount "10" @default.
• W2165087351 countsByYear W21650873512015 @default.
• W2165087351 countsByYear W21650873512016 @default.
• W2165087351 countsByYear W21650873512017 @default.
• W2165087351 countsByYear W21650873512018 @default.
• W2165087351 countsByYear W21650873512019 @default.
• W2165087351 countsByYear W21650873512021 @default.
• W2165087351 crossrefType "journal-article" @default.
• W2165087351 hasAuthorship W2165087351A5007157113 @default.
• W2165087351 hasAuthorship W2165087351A5017368316 @default.
• W2165087351 hasAuthorship W2165087351A5025484018 @default.
• W2165087351 hasAuthorship W2165087351A5027940462 @default.
• W2165087351 hasAuthorship W2165087351A5048294207 @default.
• W2165087351 hasAuthorship W2165087351A5048910830 @default.
• W2165087351 hasAuthorship W2165087351A5051698789 @default.
• W2165087351 hasAuthorship W2165087351A5058327886 @default.
• W2165087351 hasAuthorship W2165087351A5060123928 @default.
• W2165087351 hasAuthorship W2165087351A5071574732 @default.
• W2165087351 hasAuthorship W2165087351A5083127780 @default.
• W2165087351 hasBestOaLocation W21650873511 @default.
• W2165087351 hasConcept C111278954 @default.
• W2165087351 hasConcept C126322002 @default.
• W2165087351 hasConcept C142724271 @default.
• W2165087351 hasConcept C168563851 @default.
• W2165087351 hasConcept C204787440 @default.
• W2165087351 hasConcept C27081682 @default.
• W2165087351 hasConcept C2776042228 @default.
• W2165087351 hasConcept C2776719499 @default.
• W2165087351 hasConcept C2776780178 @default.
• W2165087351 hasConcept C2778884479 @default.
• W2165087351 hasConcept C2781018748 @default.
• W2165087351 hasConcept C71924100 @default.
• W2165087351 hasConceptScore W2165087351C111278954 @default.
• W2165087351 hasConceptScore W2165087351C126322002 @default.
• W2165087351 hasConceptScore W2165087351C142724271 @default.
• W2165087351 hasConceptScore W2165087351C168563851 @default.
• W2165087351 hasConceptScore W2165087351C204787440 @default.
• W2165087351 hasConceptScore W2165087351C27081682 @default.
• W2165087351 hasConceptScore W2165087351C2776042228 @default.
• W2165087351 hasConceptScore W2165087351C2776719499 @default.
• W2165087351 hasConceptScore W2165087351C2776780178 @default.
• W2165087351 hasConceptScore W2165087351C2778884479 @default.
• W2165087351 hasConceptScore W2165087351C2781018748 @default.
• W2165087351 hasConceptScore W2165087351C71924100 @default.
• W2165087351 hasIssue "12" @default.
• W2165087351 hasLocation W21650873511 @default.
• W2165087351 hasLocation W21650873512 @default.
• W2165087351 hasOpenAccess W2165087351 @default.
• W2165087351 hasPrimaryLocation W21650873511 @default.
• W2165087351 hasRelatedWork W2037286162 @default.
• W2165087351 hasRelatedWork W2053463673 @default.
• W2165087351 hasRelatedWork W2121151623 @default.
• W2165087351 hasRelatedWork W2148214230 @default.
• W2165087351 hasRelatedWork W2158341479 @default.
• W2165087351 hasRelatedWork W2165224300 @default.
• W2165087351 hasRelatedWork W2610600399 @default.
• W2165087351 hasRelatedWork W3044993546 @default.
• W2165087351 hasRelatedWork W4235850376 @default.
• W2165087351 hasRelatedWork W1835095949 @default.
• W2165087351 hasVolume "106" @default.
• W2165087351 isParatext "false" @default.
• W2165087351 isRetracted "false" @default.

• next